Will I build up a tolerance to ketamine?

Most people do not, based on current evidence. A 2023 systematic review of maintenance ketamine treatment concluded that tachyphylaxis seems uncommon, and the most rigorous trial found benefit sustained through weekly maintenance at a fixed dose with no escalation required. Tolerance has been documented in a published case over a multi-year course, so it is possible, just not typical.

How is tolerance different from the effect simply wearing off?

Tolerance means the same dose produces less effect than it used to. Wearing off means the dose worked normally and the benefit faded because the effect is time-limited. They feel similar but call for different responses: wearing off is usually solved by adjusting how often you come in, while genuine tolerance would prompt a broader reassessment.

Why not just increase my dose if the effect is fading?

Because the evidence does not support it as the first move. A 2024 systematic review found no clear efficacy advantage for intravenous doses above 0.5 mg/kg, while higher doses reliably produce more intense dissociation and greater cardiovascular effects. Adjusting the interval addresses the far more common cause without adding cumulative exposure.

How often will I need maintenance infusions, and for how long?

It varies genuinely between individuals. Published protocols typically start with weekly maintenance after an initial series, then extend toward every two to three weeks, with naturalistic reports of patients maintained at six to seven week intervals. We set yours from your observed response and actively try to extend it rather than defaulting to a fixed schedule.

Is it safe to keep receiving ketamine long term?

The maintenance research to date is reasonably reassuring, with the 2023 systematic review finding serious problems uncommon across the studies reviewed. We would also be straightforward that data beyond a few years is limited, which is why we treat cumulative exposure as something to minimize and why we push intervals longer rather than shorter whenever your response allows it.

Does Ketamine Stop Working? Tolerance, Tachyphylaxis and Booster Timing

The fear underneath the question

Almost everyone who responds well to ketamine eventually asks some version of this. It usually arrives around the time the first series wears off, and it is rarely a technical question about receptor pharmacology. It is closer to: is this the best I am going to feel, and am I now on a clock?

The short answer is that the research is more encouraging than that fear suggests, but the reasoning matters, because the distinction between two different things that both feel like it stopped working is what determines what we do next.

Tolerance and relapse are not the same thing

Tolerance, or tachyphylaxis, means the same dose produces progressively less effect. You would need more drug over time to get where you used to get. Relapse means the drug worked exactly as well as it always did, and then the benefit faded because the effect is time-limited and you have gone past its duration.

From the inside these are almost indistinguishable. From a treatment standpoint they call for opposite responses. Tolerance would push toward reconsidering the whole approach. Relapse points toward a scheduling adjustment: the interval is simply longer than your response lasts.

Most of what gets described as ketamine stopping working turns out to be the second thing. Research summarized in reviews of repeated infusion protocols found that roughly half of patients maintain remission for more than two weeks after a final infusion, with one commonly cited figure putting median time to loss of response near 18 days. If your benefit reliably fades around week three and your next infusion is at week six, nothing has gone wrong with the medication. We cover the distinction from another angle in how to tell if ketamine is not working for you.

What the maintenance research shows

A systematic review of maintenance ketamine treatment for depression published in the Journal of Psychopharmacology in 2023 examined studies across intravenous, intranasal, oral, intramuscular and subcutaneous routes. Its conclusion on this specific question was direct: maintenance ketamine was effective at sustaining antidepressant effects, and tachyphylaxis, cognitive impairment, addiction and serious urinary problems all seem uncommon.

The most rigorous single trial is Phillips and colleagues, published in the American Journal of Psychiatry in 2019. Forty-one adults with treatment-resistant depression received six infusions of 0.5 mg/kg over two weeks; 59% met response criteria, typically after a median of three infusions. Responders then received four weekly maintenance infusions at the same fixed dose. Depression scores showed no significant further change during that maintenance phase, meaning benefit was sustained at a constant dose with no escalation required.

Longer-term naturalistic data points the same direction. A 12-month observation published in the Journal of Affective Disorders in 2014 followed patients receiving repeated infusions in which the interval was progressively lengthened, with one patient extended to roughly every six to seven weeks while the dose stayed the same. An earlier published protocol maintained a patient on infusions every three weeks over 15 months.

The case that shows tolerance is possible

We do not want to oversell this. A case report published in the Journal of Clinical Psychopharmacology in 2024 documented genuine tachyphylaxis in a patient who had responded well to long-term intravenous racemic ketamine for roughly two years before response gradually diminished with each infusion, requiring progressively more frequent treatment to achieve the previous benefit.

That is one patient, over a timeframe longer than most published trials run. It establishes that tolerance can develop, which is worth knowing. The authors also noted something important: whether raising the dose can overcome tachyphylaxis remains uncertain, and escalating dose in response carries its own risks.

Why we adjust spacing before dose

Given all of that, the lever we reach for first is timing rather than dose. Several reasons converge on that choice.

A 2024 systematic review and meta-analysis of ketamine dosing for depression found no clear efficacy advantage for intravenous doses above 0.5 mg/kg. Higher doses generally produce more intense dissociation and more pronounced cardiovascular effects without reliably delivering more antidepressant benefit. Meanwhile every additional milligram adds to cumulative lifetime exposure, which is the variable that matters for the long-term safety questions we discuss in ketamine and bladder health.

Dose escalation does have a legitimate role, but mostly at the front end. The KADS trial published in the British Journal of Psychiatry in 2022 found superior efficacy in a flexible-dose arm that titrated upward based on response compared with a fixed 0.5 mg/kg arm. That is about finding your effective dose initially, which is a different problem from chasing a fading response later.

What finding your interval looks like

In practice this is empirical rather than formulaic. After an initial series we want to know, specifically, how long your response actually holds. Not roughly — specifically. Patients who track mood even loosely give us far better information to work with than those relying on recall, because memory of mood is notoriously distorted by current mood.

From there the goal is the longest interval that reliably holds you, rather than the shortest one you would tolerate. Published protocols and guidelines generally start with weekly maintenance after induction, then extend toward every two to three weeks and sometimes considerably further, individualized by when symptoms actually return.

If your interval keeps needing to shorten over time, that is the pattern worth flagging, and it is the point at which we would look at the whole picture rather than simply booking you sooner. Other medications matter here too: benzodiazepine dose has been associated with shorter duration of ketamine's effect, which we cover in ketamine and benzodiazepines.

What we do at Music City Ketamine

We do not sell open-ended infusion packages, and we do not put patients on automatic recurring schedules that continue regardless of whether they are still needed. Both practices tend to produce more infusions than the clinical picture justifies.

After your initial series we set an interval based on your observed response and then actively try to extend it. Some patients space out steadily over months. Some settle at a stable interval and stay there. Some do a series, feel well for a long stretch, and return only when they notice symptoms creeping back, which is a perfectly reasonable pattern. Our approach is described in maintenance protocols and how many sessions you need.

Honest expectations

Ketamine is FDA-approved as an anesthetic; its use for depression is off-label. Esketamine is FDA-approved for treatment-resistant depression.

Based on current evidence, most people do not develop meaningful tolerance to ketamine's antidepressant effect, and maintenance treatment sustains benefit at a stable dose for most patients studied. Tolerance can occur, has been documented, and appears uncommon. Long-term data beyond a few years remains genuinely limited, and we would rather tell you that than imply more certainty than exists.

What we can say is that if your response is fading, the first question is not whether ketamine has stopped working. It is whether the spacing matches your actual duration of benefit. That is usually a solvable problem. Pricing is in what ketamine therapy costs, and duration is covered in how long ketamine therapy lasts.